Skip to main content
. Author manuscript; available in PMC: 2019 Feb 6.
Published in final edited form as: Curr Alzheimer Res. 2014;11(7):655–663. doi: 10.2174/1567205011666140812114037

Fig. (5). IVIG regulates plasma levels of cytoskeletal plasticity mRNAs.

Fig. (5)

A) Three months of IVIG preserved plasma levels of select mRNAs regulating cytoskeletal function. Heat map (red to green = increasing mRNA levels) shows that, compared to placebo, IVIG treatment resulted in 40–50% higher expression levels of transcripts encoding microtubule-associated protein 1b (MAP1b), neurofilament heavy chain subunit (NEFH), A kinase anchor protein (AKAP), nestin (NES), Homer1 (HOMER1), and activity-regulated cytoskeletal-associated protein (ARC). Levels of these transcripts were not significantly different between the baseline and IVIG group. B) Six months of IVIG resulted in ~50% higher levels of NEFH, AKAP, NES, and ARC compared to placebo. Levels of these transcripts were not significantly different between the baseline and IVIG group. n = 12/group *, p< 0.01, **, p< 0.001 via one-way ANOVA with Bonferroni’s post hoc test for multiple comparisons. Other abbreviations: ACTB (β-actin), TUBB2C (β-tubulin), MAP2 (microtubule-associated protein 2), NFEL and NFEM (neurofilament light and medium chain subunits), UTRN (utrophin).